眼内缓释药物的研究进展  

Research progress of intraocular sustained-release drugs

作　　者：郭昭兴 万修华[1] Guo Zhaoxing;Wan Xiuhua(Beijing Tongren Eye Center,Beijing Tongren Hospital,Capital Medical University,Beijing Key Laboratory of Ophthalmology and Visual Sciences,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院、北京同仁眼科中心、眼科学与视觉科学北京市重点实验室,100730

出　　处：《国际眼科纵览》2023年第3期218-222,共5页International Review of Ophthalmology

基　　金：北京市医院管理中心临床医学发展专项经费(XMLX202133);国家自然科学基金(82171037)。

摘　　要：眼内缓释药物具有给药间隔长,患者依从性高等特点。近年来,新型抗血管内皮生长因子缓释装置(如雷珠单抗端口给药系统)已进入III期临床试验,试行治疗年龄相关性黄斑变性;地塞米松缓释制剂(Ozurdex、Dexycu、Dextenza)的适应证进一步扩大,已用于视网膜静脉阻塞、非感染性葡萄膜炎及糖尿病性黄斑水肿的治疗;用于眼内炎、青光眼、胱氨酸病的缓释滴眼液更有望取代传统滴眼液改善患者的治疗质量。Intraocular extended-release drugs have the characteristics of long administration interval and high patient compliance.In recent years,new anti-vascular endothelial growth factor extended-release devices,such as Port Delivery System with Ranibizumab,have entered phase III clinical trials for treatment of age-related macular degeneration;the indications for dexamethasone extended-release formulations(Ozurdex,Dexycu,Dextenza)have been further expanded and have been used for retinal vein obstruction,non-infectious uveitis,and diabetic macular edema treatment;extended-release drops for the treatment of endophthalmitis,glaucoma,and cystine disease are expected to to improve the quality of patient care by replacing traditional eye drops.

关 键 词：药物缓释系统 地塞米松 抗血管内皮生长因子 滴眼液 

分 类 号：R943[医药卫生—药剂学]